Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xeris Biopharma Holdings (XERS) Gross Profit (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Gross Profit for 6 consecutive years, with $74.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Profit rose 47.88% year-over-year to $74.9 million, compared with a TTM value of $249.3 million through Dec 2025, up 49.95%, and an annual FY2025 reading of $249.3 million, up 49.95% over the prior year.
  • Gross Profit was $74.9 million for Q4 2025 at Xeris Biopharma Holdings, up from $63.4 million in the prior quarter.
  • Across five years, Gross Profit topped out at $74.9 million in Q4 2025 and bottomed at $5.5 million in Q2 2021.
  • Average Gross Profit over 5 years is $33.7 million, with a median of $32.6 million recorded in 2023.
  • The sharpest move saw Gross Profit skyrocketed 271.1% in 2022, then rose 1.39% in 2024.
  • Year by year, Gross Profit stood at $16.8 million in 2021, then skyrocketed by 59.83% to $26.9 million in 2022, then skyrocketed by 37.12% to $36.8 million in 2023, then soared by 37.48% to $50.6 million in 2024, then soared by 47.88% to $74.9 million in 2025.
  • Business Quant data shows Gross Profit for XERS at $74.9 million in Q4 2025, $63.4 million in Q3 2025, and $59.6 million in Q2 2025.